Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study noted that combining oral acitretin with narrowband ultraviolet B therapy may reduce treatment time and dosages for psoriasis, potentially lowering the long-term skin cancer risk.

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

In this study, Diane was reported to effectively treat acne, seborrhoea, androgenic alopecia, and mild hirsutism in hirsute women, with its effectiveness influenced by the severity and duration of the condition.

This study found that oxybenzone is very stable under light exposure, contradicting previous findings of its oxidation to semiquinone after solar irradiation.

This study found that CPA-loaded nanoparticles, particularly SLN formulations, increased CPA epidermal penetration compared to a conventional cream and may reduce side effects in treating androgen-dependent conditions.

In this study, analysis of FDA data revealed a substantial risk of dermatologic adverse events with aromatase inhibitors, especially anastrozole and exemestane, highlighting the importance of dermatologic monitoring during such therapies.

In this study, pioglitazone treatment in patients with lichen planopilaris showed limited success, with significant improvement seen in only a minority of cases.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.

In this study, ozenoxacin was found to inhibit sebum production in insulin- and 5α-DHT-differentiated hamster sebocytes in a dose-dependent manner, suggesting potential benefits in acne management by combining antimicrobial activity against C. acnes with reduced sebum production.

This study found that topical alpha-terthienyl combined with UVA radiation rapidly induced dose-dependent cutaneous photosensitization in guinea pigs, suggesting potential for photochemotherapy in skin disorders without future carcinogenic risks.

In this case report, a patient on low-dose sorafenib for hepatocellular carcinoma developed a rare and severe facial acneiform eruption without other skin side effects, which improved only minimally with topical treatment.

This study describes a multifunctional hydrogel system designed to treat androgenetic alopecia by integrating nanozymes for reactive oxygen species clearance and melanin nano photothermal agents to enhance hair follicle health, suggesting potential for multi-target precision therapy and improved hair growth.

This study found that Soluplus and L-ascorbyl 2,6-dipalmitate nanoparticles may improve minoxidil's skin permeability through stable hydrophobic interactions, enhancing its potential for targeted skin application.

In this study, topical azelaic acid cream 20% was observed to show acceptable efficacy for treating localized alopecia areata of the scalp, offering a potential therapeutic alternative to topical clobetasol ointment 0.05%.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.

This meeting summary discusses insights from leading dermatologists on scalp management and topical ketoconazole use, but it reports no new research findings.

Pioglitazone may help treat lichen planopilaris, but more research is needed.

Azathioprine treatment led to rapid hair regrowth in a woman with alopecia universalis.

This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.

This study found that OZiva+ advanced hair growth serum significantly increased hair follicle length and showed no irritation, indicating it may be a safer alternative to traditional hair loss treatments like minoxidil.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This study found that most chronic alopecia areata patients treated with azathioprine, methotrexate, or cyclosporine continued treatment for at least 12 months, often requiring concurrent low-dose prednisolone.

This article reviews therapeutic advances published between December 1986 and December 1987 but reports no new research findings; readers are advised to consult the original articles before considering new therapies.

This review found topical ketoconazole to be highly effective against Malassezia-related skin conditions, though other treatments may outperform it for Tinea and Candida infections.

This phase 2 trial found that SM04554, a Wnt signaling modulator, was well-tolerated and increased follicle counts in males with androgenetic alopecia, suggesting potential for promoting hair growth.

This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.

This review discusses valproic acid as a common antiseizure medication associated with alopecia and highlights the need for its inclusion in relevant medical guides, without presenting new clinical findings.